Streetbeat News

Products Services

TSLA

Tesla Inc (NASDAQ:TSLA) plans to open a new showroom in Connecticut this fall, despite the state's ban on direct sales. The company will use a loophole that allows for direct sales on tribal land. The showroom will be located at The Shops at Mohegan Sun, on the sovereign tribal land of the Mohegan tribe. This move could be seen as a workaround of the Connecticut state law against direct sales.

Portfolio Pulse from Anan Ashraf

July 27, 2023 | 12:11 pm

UNVR

Univar Solutions Inc. (NYSE:UNVR) has expanded its distribution relationship with Kalsec Inc. to include advanced hop ingredients in the United States. This agreement builds on their existing partnership for distribution of Kalsec's natural taste and sensory, colors, and food protection solutions in Mexico, Colombia, and Europe. Kalsec is a leader in hops innovation and has been providing the brewing and beverage industries with advanced hop solutions for over 40 years.

Portfolio Pulse from Happy Mohamed

July 27, 2023 | 12:10 pm

FCEL

FuelCell Energy has signed a long-term service agreement with Noeul Green Energy and established a Memorandum of Understanding (MOU) with Gyeonggi Green Energy. This could potentially expand FuelCell's market presence in the renewable energy sector.

Portfolio Pulse from Bill Haddad

July 27, 2023 | 12:08 pm

AKTX

Akari Therapeutics (NASDAQ:AKTX) has been granted orphan drug designation by the European Commission for nomacopan, a treatment in hematopoietic stem cell transplantation. This follows a positive opinion from the European Medicines Agency in June. The company is currently conducting a Phase 3 study of nomacopan in pediatric HSCT-TMA and plans to begin a Phase 3 trial in adult HSCT-TMA in 2024. The orphan drug designation is in addition to the Rare Pediatric Disease, Orphan Drug, and Fast Track designations already granted by the U.S. FDA.

Portfolio Pulse from Happy Mohamed

July 27, 2023 | 12:08 pm

TSLA

A recent survey conducted by Bloomberg indicates a shift in perception of Tesla's CEO, Elon Musk, among the earliest owners of Tesla's Model 3. While the car continues to receive high praise, Musk's approval ratings have significantly dropped, with some respondents citing Musk as the reason for switching to another brand. Despite the criticism towards Musk, Model 3 owners remain overwhelmingly satisfied with their vehicles, with 96% of them considering electric options for their next vehicle purchase.

Portfolio Pulse from Benzinga Neuro

July 27, 2023 | 11:49 am

AAPL

SSNLF

Samsung (OTC:SSNLF) plans to manufacture its newest foldable smartphones, the Galaxy Z Flip5 and Galaxy Z Fold5, in its factory in northern India, aiming to tap into the growing Indian premium smartphone market. The company is offering special deals to attract cost-conscious buyers and is expanding its retail presence by 30-40% compared to last year. Samsung's move follows Apple Inc (NASDAQ:AAPL) which also plans on making its upcoming flagship iPhones in India.

Portfolio Pulse from Shomik Sen Bhattacharjee

July 27, 2023 | 11:25 am

AQST

Aquestive Therapeutics has released topline pharmacokinetic data from its crossover study AQ109103 for Anaphylm (Epinephrine) Sublingual Film. The company plans to submit a pivotal PK study protocol to the FDA in early August and expects to commence a pivotal PK trial in Q4.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 11:22 am

NEO

NeoGenomics has announced that Medicare will cover its RaDaR assay for minimal residual disease and recurrence in breast cancer. This is a significant development for the company as it expands the potential market for its product.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 11:16 am

MRSN

Mersana Therapeutics announced that its UPLIFT clinical trial of Upifitamab Rilsodotin did not meet its primary endpoint.

Portfolio Pulse from Bill Haddad

July 27, 2023 | 11:11 am

BHVN

The FDA has informed Biohaven that it will not review the NDA application for troriluzole as the study's primary endpoint was not met. Biohaven may request a Type A meeting within 30 days to address FDA's concerns. Updates regarding the meeting will be provided after the upcoming regulatory interaction.

Portfolio Pulse from Bill Haddad

July 27, 2023 | 11:09 am